Navigation Links
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units
Date:1/14/2014

s and Over-the-Counter (OTC) products in more than 60 countries, and operates a global branded specialty pharmaceutical business focused in the Women's Health, Urology, Gastroenterology and Dermatology therapeutic categories.  Actavis also has a portfolio of five biosimilar products in development in Women's Health and Oncology.  Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement

Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with financial projections; successful integration of the Warner Chilcott acquisition and the ability to recognize the anticipated synergies and benefits of the Warner Chilcott acquisition; the impact of competitive products and pricing; periodic dependence on a small number of products for a material source of net revenue or income; the timing and success of product launches; the difficulty of predicting the timing or outco
'/>"/>

SOURCE Actavis plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Actavis to Host 2014 Investor Meeting January 31 in New York
2. Actavis and Warner Chilcott Receive U.S. FTC Clearance for Actavis Proposed Acquisition of Warner Chilcott
3. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
4. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
5. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
6. Actavis Proposed Acquisition of Warner Chilcott Recommended for Approval by Leading Proxy Advisory Firms
7. Actavis Names James DArecca Chief Accounting Officer
8. Actavis Receives Approval from French Competition Authority for Pending Warner Chilcott Acquisition
9. Actavis Announces New Senior Unsecured Term Loan Credit and Guaranty Agreement
10. Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
11. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... EPODURE Biopump demonstrates safety and efficacy for four months ... Review Board confirms safety and efficacy of low dose ... trial with higher doses-- Biopump may offer alternative to ... Medgenics (AIM: MEDU/MEDG), today announced that the EPODURE ...
... FRANCISCO, Calif., Feb. 3 Rigel,Pharmaceuticals, Inc. (Nasdaq: ... will delay,further partnership discussions regarding R788 until after ... are available. The company expects that,these ... the understanding of R788,s potential and may therefore,drive ...
Cached Medicine Technology:Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease 2Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease 3Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease 4Medgenics Announces Positive Data From Phase I/II Clinical Trial of EPODURE Treatment of Anemia in Chronic Kidney Disease 5Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 2Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 3Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 4Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results 5
(Date:4/17/2014)... N.C. April 17, 2014 Meaningful long-term ... advanced cancer of the abdomen when treated with ... according to a first-of-its-size analysis by physicians at ... Baptist has the largest reported, single-center experience with ... A. Levine, M.D., and analysis of 20 years, ...
(Date:4/17/2014)... India,s shocking rates of suicide are highest in areas ... tiny smallholdings less than one hectare and ... coffee, that are highly susceptible to global price fluctuations. ... studies that point to a crisis in key areas ... nation,s economy during the 90s. Researchers say that policy ...
(Date:4/17/2014)... Professor Patrick Johnston, whose work has transformed cancer care ... of the European Academy of Cancer Sciences., The Academy, ... body of highly distinguished oncologists and cancer researchers which ... cancer in Europe. , Professor Johnston, whose leadership has ... the bottom of the UK league table to near ...
(Date:4/16/2014)... Consider the marvel of the embryo. It begins as a ... they multiply to become the cells of our lungs, muscles, ... , Now, in a feat of reverse tissue engineering, Stanford ... that allows embryonic cells to proliferate and transform into all ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
Breaking Medicine News(10 mins):Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3
... UNICEF is making a difference in Somalia despite difficult circumstances; ... Urges world to remember Somali ... today ended a five-day visit to the troubled east African,nation ... plight of that,country,s children., (Photo: http://www.newscom.com/cgi-bin/prnh/20080703/NYTH023 ), ...
... Organizations, SOUTH PORTLAND, Maine, July 3 ... $1.4 million to community organizations,throughout Maine in 2007. ... the recently released Maine Community Relations,Report - 2007. ... ., "All associates at Anthem Blue Cross ...
... available in Spanish . , ,Scientists of the ... have confirmed that stem cells from human umbilical cord blood ... diseases such as hepatitis, and therefore mean an effective alternative ... be shortly published in the renowned journal Cell ...
... Pa., July 3 Eileen Connelly,Executive Director of ... called on the Pennsylvania School,Employees, Retirement System (PSERS) ... steering clear of an investment management firm,affiliated with ... lost,money for PSERS annuitants and whose past is ...
... Juicy Juice will encourage Hispanics to ... exercise and eat ... the return of last year,s successful junior soccer,tournament, Copita Juicy Juice. ... summer, and include the participation of over 600,children and more than ...
... ON, Canada Titanium implants were successfully introduced ... the,rehabilitation of edentulous jaws. After 40 years of ... frequently used,biomaterial in oral implantology, and titanium-based materials ... several parts of the,body. , There are some ...
Cached Medicine News:Health News:UNICEF Ambassador Clay Aiken Visits North-West Somalia 2Health News:UNICEF Ambassador Clay Aiken Visits North-West Somalia 3Health News:Anthem Blue Cross and Blue Shield Issues Community Report for 2007 2Health News:Stem cells from umbilical cord used in the treatment of hepatic diseases 2Health News:Major Union Questions PA Pension Fund, Calls on PSERS to Protect Workers, Retirees 2Health News:Nestle Juicy Juice Kicks Off Summer Promoting Nutritious, Active Lifestyle Choices Among Latino Children, Families 2Health News:Nestle Juicy Juice Kicks Off Summer Promoting Nutritious, Active Lifestyle Choices Among Latino Children, Families 3
Ergotec Vetriretinal Instrument System. Extra fine angled tips (3 mm). 20 ga. shaft tapering to 23 ga., 10 mm from tip. Overall length from rear rotation knob to tip....
Ergotec Vetriretinal Instrument System. Ultra-fine 3.35 mm tips. Angled 55 degrees. 20 gauge shaft. 30 mm in length. Overall length from rear rotation knob to tip....
For use with the Landers Vitrectomy Lens set (MVS 1079A). Shafts angled 45 degrees with curved grooved blades for holding the Landers vitrectomy lenses. Polished finish....
Ergotec Vetriretinal Instrument System. 2 mm pointed tips with 0.6 mm platform. 20 gauge shaft tapers to 23 gauge....
Medicine Products: